Geographic Area – Page 2

Pfizer Pays $1.25B Upfront to 3SBio, Joining the PD-1 x VEGF Race with Licensing Deal for SSGJ-707

3 weeks ago talkbio0Tagged Cancer Therapeutic Procedure, China, Drug Development, Licensing Deal, Neoplasms, PD-1/VEGF bispecific antibody, Pfizer, SSGJ-707, upfront payment

Pfizer; 3SBio; PD-1/VEGF bispecific antibody; SSGJ-707; oncology; upfront payment; licensing deal; cancer therapy; China; drug development

Leqembi’s Expansion and Blood Test Impact: Analyst Sees Gradual Uptake Boost

3 weeks ago talkbio0Tagged Adoption, Alzheimer 's disease, Approved, AutoInjector, Biogen, dosing, Eisai, Hematologic Tests, launch, Leqembi, Maintenance, Market, subcutaneous, United States Food and Drug Administration

Leqembi; Eisai; Biogen; Alzheimer’s disease; FDA approval; blood test; launch; maintenance dosing; autoinjector; subcutaneous; market adoption

Novo Nordisk CEO Departs Amid Weight-Loss Drug Market Pressures; Flagship Biotech Appoints CEO from Scholar Rock

4 weeks ago talkbio0Tagged Appointments, biotech, CEO, Challenge, departure - ActRelationshipType, Eli Lilly competition, Flagship, Lars Fruergaard Jørgensen, Market, Nordisk, Obesity, Scholar Rock

Novo Nordisk; CEO departure; Lars Fruergaard Jørgensen; obesity drugs; weight-loss market; Eli Lilly competition; market challenges; Flagship Biotech; CEO appointment; Scholar Rock

Three-Month Drought in U.S. Biotech IPOs: Recent Developments and Context

4 weeks ago talkbio0Tagged Droughts, IPO, Market, stocks

biotech IPO; biotech market; IPO drought; 2025; biotech fundraising; biotech stocks

Sanofi Commits $20 Billion to U.S. R&D and Manufacturing by 2030

4 weeks ago talkbio0Tagged domestic partnerships, drug launches, Investments, Manufacturing, R&D, sanofi, Surgical construction, United States

Sanofi; $20 billion investment; U.S. manufacturing; R&D; job creation; drug launches; domestic partnerships

Bristol Myers CEO: America’s Biopharma Leadership Not Guaranteed

4 weeks ago talkbio0Tagged Americas, Biopharma, CEO, Chris Boerner, dealmaking, global competitiveness, Growth, innovation, Myers, squibb

Bristol Myers Squibb; CEO; Chris Boerner; biopharma; Americas; global competitiveness; dealmaking; innovation; growth portfolio

GSK and iTeos End Belrestotug TIGIT Program After Disappointing Lung Cancer Results

4 weeks ago talkbio0Tagged belrestotug, Clinical Trials, dostarlimab, Drug Development, Galaxies, immuno-oncology, iTeos, Lung-201, Malignant neoplasm of lung, Progression-Free Survival, SmithKline Beecham, TIGIT gene

GSK; iTeos; belrestotug; TIGIT; lung cancer; dostarlimab; clinical trial; drug development; GALAXIES Lung-201; immuno-oncology; progression-free survival